相似文献
1
Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review.银屑病与非酒精性脂肪性肝病发病机制的研究进展。
Semin Arthritis Rheum. 2023 Apr;59:152165. doi: 10.1016/j.semarthrit.2023.152165. Epub 2023 Jan 18.
2
Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients.代谢综合征、非酒精性脂肪性肝病与银屑病关节炎及银屑病患者的肝硬度。
Clin Rheumatol. 2019 Oct;38(10):2843-2850. doi: 10.1007/s10067-019-04646-7. Epub 2019 Jun 28.
3
Non-alcoholic fatty liver disease: A sign of systemic disease.非酒精性脂肪性肝病：一种全身性疾病的体征。
Metabolism. 2017 Jul;72:94-108. doi: 10.1016/j.metabol.2017.04.011. Epub 2017 Apr 27.
4
Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.系统评价：多囊卵巢综合征与代谢综合征和非酒精性脂肪性肝病的关系。
Aliment Pharmacol Ther. 2011 Apr;33(7):801-14. doi: 10.1111/j.1365-2036.2011.04579.x. Epub 2011 Jan 20.
5
Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.非酒精性脂肪性肝病、肥胖症与代谢综合征。
Best Pract Res Clin Gastroenterol. 2014 Aug;28(4):637-53. doi: 10.1016/j.bpg.2014.07.008. Epub 2014 Jul 11.
6
Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches.非酒精性脂肪性肝病（NAFLD）作为精神疾病被忽视的代谢伴发疾病：共同途径和未来方法。
BMC Med. 2020 Oct 1;18(1):261. doi: 10.1186/s12916-020-01713-8.
7
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.非酒精性脂肪性肝病、胰岛素抵抗、代谢综合征及其与血管风险的关系。
Metabolism. 2021 Jun;119:154770. doi: 10.1016/j.metabol.2021.154770. Epub 2021 Apr 14.
8
Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments.非酒精性脂肪性肝病与心血管风险：代谢方面和新的治疗方法。
Endocrine. 2011 Dec;40(3):332-43. doi: 10.1007/s12020-011-9530-x. Epub 2011 Sep 6.
9
10
Metabolic syndrome and risk factors for non-alcoholic fatty liver disease.代谢综合征与非酒精性脂肪性肝病的危险因素
Arq Gastroenterol. 2012 Jan-Mar;49(1):89-96. doi: 10.1590/s0004-28032012000100015.
引用本文的文献
1
Unmet needs in psoriatic arthritis, a narrative review.银屑病关节炎未满足的需求：一篇叙述性综述
Arch Rheumatol. 2024 May 5;39(2):159-171. doi: 10.46497/ArchRheumatol.2024.10710. eCollection 2024 Jun.
2
Small Intestinal Permeability and Metabolomic Profiles in Feces and Plasma Associate With Clinical Response in Patients With Active Psoriatic Arthritis Participating in a Fecal Microbiota Transplantation Trial: Exploratory Findings From the FLORA Trial.参与粪便微生物群移植试验的活动性银屑病关节炎患者的小肠通透性以及粪便和血浆中的代谢组学特征与临床反应相关：FLORA试验的探索性结果
ACR Open Rheumatol. 2023 Nov;5(11):583-593. doi: 10.1002/acr2.11604. Epub 2023 Sep 22.
3
Development of prediction model for alanine transaminase elevations during the first 6 months of conventional synthetic DMARD treatment.常规合成改善病情抗风湿药物治疗最初 6 个月期间丙氨酸氨基转移酶升高的预测模型的建立。
Sci Rep. 2023 Aug 9;13(1):12943. doi: 10.1038/s41598-023-39694-2.
本文引用的文献
1
Autophagy impairment in liver CD11c cells promotes non-alcoholic fatty liver disease through production of IL-23.肝 CD11c 细胞自噬受损通过产生 IL-23 促进非酒精性脂肪性肝病。
Nat Commun. 2022 Mar 17;13(1):1440. doi: 10.1038/s41467-022-29174-y.
2
Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies.慢性斑块状银屑病患者非酒精性脂肪性肝病的发病风险：一项观察性研究的更新系统评价和荟萃分析。
J Endocrinol Invest. 2022 Jul;45(7):1277-1288. doi: 10.1007/s40618-022-01755-0. Epub 2022 Feb 11.
3
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.里莎鲁单抗治疗活动性银屑病关节炎的疗效和安全性：随机、双盲、3 期 KEEPsAKE 1 试验的 24 周结果。
Ann Rheum Dis. 2022 Feb;81(2):225-231. doi: 10.1136/annrheumdis-2021-221019. Epub 2021 Dec 15.
4
Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies.银屑病患者的非酒精性脂肪性肝病（NAFLD）：系统性治疗对肝脏影响的综述
Psoriasis (Auckl). 2021 Dec 7;11:151-168. doi: 10.2147/PTT.S342911. eCollection 2021.
5
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.利纳西普治疗活动性银屑病关节炎的疗效和安全性：随机、双盲、III 期 KEEPsAKE 2 试验的 24 周结果。
Ann Rheum Dis. 2022 Mar;81(3):351-358. doi: 10.1136/annrheumdis-2021-221048. Epub 2021 Nov 23.
6
Role of Leptin in Non-Alcoholic Fatty Liver Disease.瘦素在非酒精性脂肪性肝病中的作用。
Biomedicines. 2021 Jun 30;9(7):762. doi: 10.3390/biomedicines9070762.
7
Psoriasis Prevalence in Adults in the United States.美国成年人银屑病患病率。
JAMA Dermatol. 2021 Aug 1;157(8):940-946. doi: 10.1001/jamadermatol.2021.2007.
8
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.利纳西普治疗中重度斑块型银屑病的长期疗效和安全性：LIMMitless 开放性扩展试验 3 年以上随访的中期分析。
Br J Dermatol. 2021 Dec;185(6):1135-1145. doi: 10.1111/bjd.20595. Epub 2021 Sep 21.
9
Mechanisms and disease consequences of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的机制及疾病后果
Cell. 2021 May 13;184(10):2537-2564. doi: 10.1016/j.cell.2021.04.015.
10
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.替度鲁单抗治疗活动性银屑病关节炎患者的疗效和安全性：一项随机、双盲、安慰剂对照、多剂量、52 周的 IIb 期研究结果。
Ann Rheum Dis. 2021 Sep;80(9):1147-1157. doi: 10.1136/annrheumdis-2020-219014. Epub 2021 May 13.
Zotero 插件